The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity.
 
David R. Spigel
Leadership - TriStar Centennial Medical Center
Consulting or Advisory Role - Aptitude Health (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Dracen (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iksuda Therapeutics (Inst); Illumina (Inst); Merck (Inst); Molecular Templates (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Seagen (Inst); Takeda (Inst); TRIPTYCH Health Partners (Inst); TRM Oncology (Inst); Williams and Connolly (Inst)
Research Funding - Aeglea Biotherapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BIND Therapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GRAIL (Inst); ImClone Systems (Inst); Immunogen (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Molecular Partners (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Takeda (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; GlaxoSmithKline; Janssen Oncology; Merck; Novartis; Pfizer; Seagen; Spectrum Pharmaceuticals; Takeda
 
Luis G. Paz-Ares
Leadership - Altum Sequencing; European Medicines Agency (I); Genomica
Honoraria - Advanced Accelerator Applications; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Incyte; Ipsen; Lilly; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Roche/Genentech; Sanofi; Servier; Sysmex
Research Funding - AstraZeneca; Bristol-Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Yuanbin Chen
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Genentech; Pfizer; Takeda
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Guardant Health; Lilly; Merck; Novartis; Roche/Genentech; Takeda
Research Funding - Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Helsinn Therapeutics; Ipsen; Roche/Genentech
Expert Testimony - AstraZeneca; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Ipsen
 
Maria Jove
Honoraria - Boehringer Ingelheim
Travel, Accommodations, Expenses - MSD; Roche; Takeda
 
Oscar Juan-Vidal
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Pfizer; Roche/Genentech; Takeda
Research Funding - AstraZeneca Spain (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche/Genentech
 
Patricia Rich
No Relationships to Disclose
 
Theresa M. Hayes
No Relationships to Disclose
 
M Vanesa Gutierrez Calderon
No Relationships to Disclose
 
Reyes Bernabe Caro
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Roche; Takeda
 
Alejandro Navarro
Consulting or Advisory Role - Boehringer Ingelheim; Pfizer
Speakers' Bureau - Roche
Expert Testimony - Oryzon Genomics
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Afshin Dowlati
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Seagen; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Bayer (Inst); Incuron (Inst); Ipsen (Inst); Loxo (Inst); Regeneron (Inst); Seagen (Inst); Symphogen (Inst); Takeda (Inst); Tesaro (Inst)
 
Bin Zhang
Employment - Ipsen
Stock and Other Ownership Interests - Ipsen
Patents, Royalties, Other Intellectual Property - Ipsen
 
Yan Moore
Employment - Ipsen
Leadership - Ipsen
Stock and Other Ownership Interests - Ipsen
Travel, Accommodations, Expenses - Ipsen
 
Haofei Tiffany Wang
Employment - Ipsen
Stock and Other Ownership Interests - Ipsen
 
Jaba Kokhreidze
Employment - Ipsen
Consulting or Advisory Role - BMSi; Constellation Pharmaceuticals; JKMD Global Medical Solutions; Tocagen
 
Natalya Nazarenko
Employment - Ipsen
Stock and Other Ownership Interests - Ipsen
 
Santiago Ponce Aix
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche
Travel, Accommodations, Expenses - AstraZeneca; Merck; Roche
 
Paul Bunn
Consulting or Advisory Role - Ascentage Pharma; AstraZeneca; Celgene; CStone Pharmaceuticals; Genentech; Imedex; Ipsen; Lilly; Merck